Geniposide, in combination with chlorogenic acid, has been reported to display protective effects on gut barrier function by increasing the expression of ZO-1 and occludin to ameliorate non-alcoholic fatty liver disease [98]. Here, OCLN is linked to metabolic dysfunction-associated steatotic liver disease.